Cargando…

Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

SIMPLE SUMMARY: The molecular and clinical features of KRAS-mutated lung cancer patients treated with immunotherapy have yet to be well characterized, and little information is known about resistance in these patients. The goal of this study is to better understand the survival results of KRAS-mutat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Dan, Li, Haiqing, Mambetsariev, Isa, Mirzapoiazova, Tamara, Chen, Chen, Fricke, Jeremy, Kulkarni, Prakash, Villaflor, Victoria, Arvanitis, Leonidas, Hamilton, Stanley, Afkhami, Michelle, Pillai, Raju, Armstrong, Brian, Erhunmwunsee, Loretta, Massarelli, Erminia, Sattler, Martin, Amini, Arya, Salgia, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562655/ https://www.ncbi.nlm.nih.gov/pubmed/36230855 http://dx.doi.org/10.3390/cancers14194933

Ejemplares similares

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
por: Sayer, Michael R., et al.
Publicado: (2023)

Precision medicine and actionable alterations in lung cancer: A single institution experience
por: Mambetsariev, Isa, et al.
Publicado: (2020)

Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations
por: Reckamp, Karen L, et al.
Publicado: (2020)

Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors
por: Zhao, Dan, et al.
Publicado: (2021)

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020)

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
por: Mohanty, Atish, et al.
Publicado: (2023)

Integration of artificial intelligence in lung cancer: Rise of the machine
por: Ladbury, Colton, et al.
Publicado: (2023)

Disparate outcomes in nonsmall cell lung cancer by immigration status
por: Chau, Brittney, et al.
Publicado: (2021)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
por: Juarez-Vignon Whaley, Juan Jose, et al.
Publicado: (2023)

Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer
por: Zarinshenas, Reza, et al.
Publicado: (2023)

Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions
por: Pathak, Ranjan, et al.
Publicado: (2021)

Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report
por: Pharaon, Rebecca R., et al.
Publicado: (2022)

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer
por: Roosan, Moom R., et al.
Publicado: (2021)

Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
por: Roosan, Moom R., et al.
Publicado: (2021)

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
por: Sattler, Martin, et al.
Publicado: (2023)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology
por: Mambetsariev, Isa, et al.
Publicado: (2019)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells
por: Mirzapoiazova, Tamara, et al.
Publicado: (2019)

A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer
por: Ramisetty, Sravani, et al.
Publicado: (2023)

Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence
por: Pharaon, Rebecca, et al.
Publicado: (2020)

Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS
por: Kalvala, Arjun, et al.
Publicado: (2019)

The DNA walk and its demonstration of deterministic chaos—relevance to genomic alterations in lung cancer
por: Hewelt, Blake, et al.
Publicado: (2019)

A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer
por: Mohanty, Atish, et al.
Publicado: (2020)

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models
por: Salgia, Ravi, et al.
Publicado: (2018)

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients
por: Poroyko, Valeriy, et al.
Publicado: (2018)

HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression
por: Mirzapoiazova, Tamara, et al.
Publicado: (2015)

Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
por: Fricke, Jeremy, et al.
Publicado: (2020)

Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
por: Wing, Sam E., et al.
Publicado: (2022)

Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines
por: Mirzapoiazova, Tamara, et al.
Publicado: (2020)

Heuristic value-based framework for lung cancer decision-making
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Clinical Network Systems Biology: Traversing the Cancer Multiverse
por: Mambetsariev, Isa, et al.
Publicado: (2023)

Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma
por: Garcia, Diogo, et al.
Publicado: (2023)

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
por: Won, Brian, et al.
Publicado: (2016)

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer
por: Mirzapoiazova, Tamara, et al.
Publicado: (2021)

Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?
por: Juarez-Vignon Whaley, Juan Jose, et al.
Publicado: (2023)

Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report
por: Roth, Katherine G., et al.
Publicado: (2020)

The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer
por: Lennon, Frances E., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_88ssd4fc3b87o2gb246nnsv4nf